We previously highlighted that cDC2s, cDC1s and pDCs from the tumor microenvironment displayed higher levels of co-stimulatory molecules compared to the circulating DC subsets (7), potentially explaining distinct CLR expression patterns observed in blood and tumor of melanoma patients. The gene discussed is DCLK3; the disease is neoplasm.